Market capitalization | $74.08m |
Enterprise Value | $74.30m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 928.75 |
P/S ratio (TTM) P/S ratio | 926.00 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 398.55% |
Revenue (TTM) Revenue | $80.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Zivo Bioscience Inc:
1 Analyst has issued a forecast Zivo Bioscience Inc:
Sep '24 |
+/-
%
|
||
Revenue | 0.08 0.08 |
300%
300%
|
|
Gross Profit | 0.03 0.03 |
150%
150%
|
|
EBITDA | -14 -14 |
72%
72%
|
EBIT (Operating Income) EBIT | -14 -14 |
71%
71%
|
Net Profit | -14 -14 |
61%
61%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.
Head office | United States |
CEO | John Payne |
Employees | 8 |
Founded | 1983 |
Website | www.zivobioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.